Pain management with tapentadol: a better and safer alternative to oxycodone

Shailendra Kapoor, MD

doi:10.5055/jom.2012.0107

Authors

Shailendra Kapoor, MD

DOI:

https://doi.org/10.5055/jom.2012.0107

Abstract

no abstract

Author Biography

Shailendra Kapoor, MD

Private practice, Mechanicsville, Virginia

References

Friedmann N, Klutzaritz V, Webster L: Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag. 2011; 7(3): 193-202.

Afilalo M, Etropolski MS, Kuperwasser B, et al.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010; 30: 489-505.

Kwong WJ, Ozer-Stillman I, Miller JD, et al.: Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther. 2010; 32: 1768-1781.

Daniels S, Casson E, Stegmann JU, et al.: A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009; 25: 1551-1561.

Hale M, Upmalis D, Okamoto A, et al.: Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin. 2009; 25: 1095-1104.

Lange B, Kuperwasser B, Okamoto A, et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27: 381-399.

Christoph T, De Vry J, Schiene K, et al.: Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol. 2011; 666: 72-79.